Posted by Michael Wonder on 29 Apr 2021
Valeo Pharma’s Redesca and Redesca HP to be covered under the Ontario Public Drug Benefit Program
28 April 2021 - Additional provincial coverage expected to follow.
Valeo Pharma today announced that it has entered into a product listing agreement with the Executive Officer of the Ontario Public Drug Program for the listing of Redesca and Redesca HP, its low molecular weight heparin biosimilar, on the Ontario Drug Benefit Formulary effective 30 April 2021.
